Last 12 months
Inside the activity.
1 purchase rows · 32 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 8 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 14 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 7 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2019 Filed May 4, 2019 00:52 UTC |
SCANGOS GEORGE ADirector
|
SaleCommon Stock | 25,000 | $19.75 | $493,750.00 |
DisclosureSEC source: 0000939767-19-000111 · wf-form4_155693115338573.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,248,031 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 24, 2018. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $19.60 to $19.84. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| April 24, 2019 Filed Apr 27, 2019 00:14 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
Exercise / conversionOption (right to buy) · Derivative | 40,000 | $0.00 Strike: $5.56 | $0.00 |
DisclosureSEC source: 0000939767-19-000099 · wf-form4_155632406024567.xml · derivative · entry 5 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 40,000 shares Expires 2019-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option, representing the right to purchase a total of 402,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 21, 2016. Read SEC document |
| April 24, 2019 Filed Apr 27, 2019 00:14 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
SaleCommon Stock | 40,000 | $20.75 | $830,000.00 |
DisclosureSEC source: 0000939767-19-000099 · wf-form4_155632406024567.xml · nonDerivative · entry 2 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2018. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.52 to $21.19. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| April 24, 2019 Filed Apr 27, 2019 00:14 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
Exercise / conversionCommon Stock | 40,000 | $5.56 | $222,400.00 |
DisclosureSEC source: 0000939767-19-000099 · wf-form4_155632406024567.xml · nonDerivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 90,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| April 10, 2019 Filed Apr 12, 2019 23:59 UTC |
Haley Patrick J.Sr. Vice President, Commercial
|
SaleCommon Stock | 1,000 | $24.04 | $24,040.00 |
DisclosureSEC source: 0000939767-19-000094 · wf-form4_155511356567607.xml · nonDerivative · entry 1 Haley Patrick J. · CIK 0001692954 · Sr. Vice President, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,780 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 23, 2018. F2 · balance_after: Includes 49,234 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| April 10, 2019 Filed Apr 12, 2019 23:56 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
Exercise / conversionOption (right to buy) · Derivative | 40,000 | $0.00 Strike: $5.56 | $0.00 |
DisclosureSEC source: 0000939767-19-000092 · wf-form4_155511335543491.xml · derivative · entry 5 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,000 Underlying: Common Stock · 40,000 shares Expires 2019-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option, representing the right to purchase a total of 402,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 21, 2016. Read SEC document |
| April 10, 2019 Filed Apr 12, 2019 23:56 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
SaleCommon Stock | 40,000 | $24.06 | $962,400.00 |
DisclosureSEC source: 0000939767-19-000092 · wf-form4_155511335543491.xml · nonDerivative · entry 2 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2018. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.69 to $24.24. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| April 10, 2019 Filed Apr 12, 2019 23:56 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
Exercise / conversionCommon Stock | 40,000 | $5.56 | $222,400.00 |
DisclosureSEC source: 0000939767-19-000092 · wf-form4_155511335543491.xml · nonDerivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 90,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| April 03, 2019 Filed Apr 4, 2019 00:17 UTC |
Schwab GiselaPres, Prod Dev & Med Aff & CMO
|
Exercise / conversionOption (right to buy) · Derivative | 63,109 | $7.18 Strike: $7.18 | $453,122.62 |
DisclosureSEC source: 0000939767-19-000086 · wf-form4_155433702016937.xml · derivative · entry 4 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 63,109 shares Expires 2019-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 210,000 shares of Exelixis, Inc. common stock, became fully exercisable on December 9, 2013. Read SEC document |
| April 03, 2019 Filed Apr 4, 2019 00:17 UTC |
Schwab GiselaPres, Prod Dev & Med Aff & CMO
|
SaleCommon Stock | 63,109 | $25.00 | $1,577,725.00 |
DisclosureSEC source: 0000939767-19-000086 · wf-form4_155433702016937.xml · nonDerivative · entry 2 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,513 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| April 03, 2019 Filed Apr 4, 2019 00:17 UTC |
Schwab GiselaPres, Prod Dev & Med Aff & CMO
|
Exercise / conversionCommon Stock | 63,109 | $7.18 | $453,122.62 |
DisclosureSEC source: 0000939767-19-000086 · wf-form4_155433702016937.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 379,622 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 66,250 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| April 03, 2019 Filed Apr 4, 2019 00:05 UTC |
SCANGOS GEORGE ADirector
|
SaleCommon Stock | 5,000 | $25.03 | $125,150.00 |
DisclosureSEC source: 0000939767-19-000082 · wf-form4_155433633161299.xml · nonDerivative · entry 2 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,273,031 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 24, 2018. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.06. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| April 01, 2019 Filed Apr 4, 2019 00:09 UTC |
WYSZOMIERSKI JACK LDirector
|
Exercise / conversionOption (right to buy) · Derivative | 15,000 | $0.00 Strike: $4.57 | $0.00 |
DisclosureSEC source: 0000939767-19-000084 · wf-form4_155433655136837.xml · derivative · entry 5 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2019-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 15,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 24, 2012. Read SEC document |
| April 01, 2019 Filed Apr 4, 2019 00:09 UTC |
WYSZOMIERSKI JACK LDirector
|
Exercise / conversionOption (right to buy) · Derivative | 11,250 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0000939767-19-000084 · wf-form4_155433655136837.xml · derivative · entry 4 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,250 shares Expires 2019-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 11,250 shares of Exelixis, Inc. common stock, became fully exercisable on May 14, 2009. Read SEC document |
| April 01, 2019 Filed Apr 4, 2019 00:09 UTC |
WYSZOMIERSKI JACK LDirector
|
SaleCommon Stock | 7,822 | $23.97 | $187,493.34 |
DisclosureSEC source: 0000939767-19-000084 · wf-form4_155433655136837.xml · nonDerivative · entry 3 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,209 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2018. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.88 to $24.12. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| April 01, 2019 Filed Apr 4, 2019 00:09 UTC |
WYSZOMIERSKI JACK LDirector
|
Exercise / conversionCommon Stock | 15,000 | $4.57 | $68,550.00 |
DisclosureSEC source: 0000939767-19-000084 · wf-form4_155433655136837.xml · nonDerivative · entry 2 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,031 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2019 Filed Apr 4, 2019 00:09 UTC |
WYSZOMIERSKI JACK LDirector
|
Exercise / conversionCommon Stock | 11,250 | $4.16 | $46,800.00 |
DisclosureSEC source: 0000939767-19-000084 · wf-form4_155433655136837.xml · nonDerivative · entry 1 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,031 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 7,937 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| April 01, 2019 Filed Apr 4, 2019 00:05 UTC |
SCANGOS GEORGE ADirector
|
SaleCommon Stock | 40,000 | $24.02 | $960,800.00 |
DisclosureSEC source: 0000939767-19-000082 · wf-form4_155433633161299.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,278,031 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 24, 2018. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.91 to $24.14. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| April 01, 2019 Filed Apr 4, 2019 00:01 UTC |
Hessekiel JeffreyEVP and General Counsel
|
Exercise / conversionOption (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0000939767-19-000080 · wf-form4_155433604757836.xml · derivative · entry 4 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 20,000 shares Expires 2021-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 400,000 shares of Exelixis, Inc. common stock, became fully exercisable on April 28, 2016. Read SEC document |
| April 01, 2019 Filed Apr 4, 2019 00:01 UTC |
Hessekiel JeffreyEVP and General Counsel
|
SaleCommon Stock | 20,000 | $24.03 | $480,600.00 |
DisclosureSEC source: 0000939767-19-000080 · wf-form4_155433604757836.xml · nonDerivative · entry 2 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,820 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2019. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $24.00 to $24.15. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| April 01, 2019 Filed Apr 4, 2019 00:01 UTC |
Hessekiel JeffreyEVP and General Counsel
|
Exercise / conversionCommon Stock | 20,000 | $1.70 | $34,000.00 |
DisclosureSEC source: 0000939767-19-000080 · wf-form4_155433604757836.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,820 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 45,624 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 23:58 UTC |
Garber Alan MDirector
|
SaleOption (right to buy) · Derivative | 15,000 | $0.00 Strike: $4.57 | $0.00 |
DisclosureSEC source: 0000939767-19-000078 · wf-form4_155433591000438.xml · derivative · entry 6 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2019-05-23 F4 · derivative.exercise_date: The option, representing the right to purchase a total of 15,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 24, 2012. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 23:58 UTC |
Garber Alan MDirector
|
SaleOption (right to buy) · Derivative | 15,000 | $0.00 Strike: $5.92 | $0.00 |
DisclosureSEC source: 0000939767-19-000078 · wf-form4_155433591000438.xml · derivative · entry 5 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2020-05-18 F3 · derivative.exercise_date: The option, representing the right to purchase a total of 15,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 19, 2010. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 23:58 UTC |
Garber Alan MDirector
|
SaleCommon Stock | 15,000 | $23.97 | $359,550.00 |
DisclosureSEC source: 0000939767-19-000078 · wf-form4_155433591000438.xml · nonDerivative · entry 4 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,329 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2018 and modified on February 28, 2019. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.89 to $24.14. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 23:58 UTC |
Garber Alan MDirector
|
Exercise / conversionCommon Stock | 15,000 | $4.57 | $68,550.00 |
DisclosureSEC source: 0000939767-19-000078 · wf-form4_155433591000438.xml · nonDerivative · entry 3 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,329 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 23:58 UTC |
Garber Alan MDirector
|
SaleCommon Stock | 15,000 | $24.00 | $360,000.00 |
DisclosureSEC source: 0000939767-19-000078 · wf-form4_155433591000438.xml · nonDerivative · entry 2 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,329 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2018 and modified on February 28, 2019. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 23:58 UTC |
Garber Alan MDirector
|
Exercise / conversionCommon Stock | 15,000 | $5.92 | $88,800.00 |
DisclosureSEC source: 0000939767-19-000078 · wf-form4_155433591000438.xml · nonDerivative · entry 1 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,329 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 29, 2019 Filed Mar 29, 2019 23:37 UTC |
POSTE GEORGEDirector
|
Exercise / conversionOption (right to buy) · Derivative | 15,000 | $0.00 Strike: $4.57 | $0.00 |
DisclosureSEC source: 0000939767-19-000073 · wf-form4_155390261997027.xml · derivative · entry 3 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2019-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 15,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 24, 2012. Read SEC document |
| March 29, 2019 Filed Mar 29, 2019 23:37 UTC |
POSTE GEORGEDirector
|
SaleCommon Stock | 3,860 | $23.89 | $92,215.40 |
DisclosureSEC source: 0000939767-19-000073 · wf-form4_155390261997027.xml · nonDerivative · entry 2 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,475 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2019. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.66 to $24.00. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| March 29, 2019 Filed Mar 29, 2019 23:37 UTC |
POSTE GEORGEDirector
|
Exercise / conversionCommon Stock | 15,000 | $4.57 | $68,550.00 |
DisclosureSEC source: 0000939767-19-000073 · wf-form4_155390261997027.xml · nonDerivative · entry 1 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,335 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 7,937 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| March 27, 2019 Filed Mar 29, 2019 23:41 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
Exercise / conversionOption (right to buy) · Derivative | 40,000 | $0.00 Strike: $5.56 | $0.00 |
DisclosureSEC source: 0000939767-19-000075 · wf-form4_155390288826665.xml · derivative · entry 5 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,000 Underlying: Common Stock · 40,000 shares Expires 2019-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option, representing the right to purchase a total of 402,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 21, 2016. Read SEC document |
| March 27, 2019 Filed Mar 29, 2019 23:41 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
SaleCommon Stock | 40,000 | $23.39 | $935,600.00 |
DisclosureSEC source: 0000939767-19-000075 · wf-form4_155390288826665.xml · nonDerivative · entry 2 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2018. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.08 to $23.65. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| March 27, 2019 Filed Mar 29, 2019 23:41 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
Exercise / conversionCommon Stock | 40,000 | $5.56 | $222,400.00 |
DisclosureSEC source: 0000939767-19-000075 · wf-form4_155390288826665.xml · nonDerivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 90,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| March 26, 2019 Filed Mar 28, 2019 00:31 UTC |
Haley Patrick J.Sr. Vice President, Commercial
|
Exercise / conversionOption (right to buy) · Derivative | 2,700 | $0.00 Strike: $5.18 | $0.00 |
DisclosureSEC source: 0000939767-19-000069 · wf-form4_155373307151841.xml · derivative · entry 5 Haley Patrick J. · CIK 0001692954 · Sr. Vice President, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,700 shares Expires 2019-03-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 2,700 shares of Exelixis, Inc. common stock, became fully exercisable on March 30, 2016. Read SEC document |
| March 26, 2019 Filed Mar 28, 2019 00:31 UTC |
Haley Patrick J.Sr. Vice President, Commercial
|
SaleCommon Stock | 2,700 | $23.47 | $63,369.00 |
DisclosureSEC source: 0000939767-19-000069 · wf-form4_155373307151841.xml · nonDerivative · entry 2 Haley Patrick J. · CIK 0001692954 · Sr. Vice President, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,780 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 23, 2018. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.33 to $23.63. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| March 26, 2019 Filed Mar 28, 2019 00:31 UTC |
Haley Patrick J.Sr. Vice President, Commercial
|
Exercise / conversionCommon Stock | 2,700 | $5.18 | $13,986.00 |
DisclosureSEC source: 0000939767-19-000069 · wf-form4_155373307151841.xml · nonDerivative · entry 1 Haley Patrick J. · CIK 0001692954 · Sr. Vice President, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,480 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 49,234 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| March 25, 2019 Filed Mar 28, 2019 00:33 UTC |
Schwab GiselaPres, Prod Dev & Med Aff & CMO
|
Exercise / conversionOption (right to buy) · Derivative | 100,000 | $0.00 Strike: $7.18 | $0.00 |
DisclosureSEC source: 0000939767-19-000071 · wf-form4_155373321327183.xml · derivative · entry 4 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,109 Underlying: Common Stock · 100,000 shares Expires 2019-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 195,409 shares of Exelixis, Inc. common stock, became fully exercisable on December 9, 2013. Read SEC document |
| March 25, 2019 Filed Mar 28, 2019 00:33 UTC |
Schwab GiselaPres, Prod Dev & Med Aff & CMO
|
SaleCommon Stock | 100,000 | $23.14 | $2,314,000.00 |
DisclosureSEC source: 0000939767-19-000071 · wf-form4_155373321327183.xml · nonDerivative · entry 2 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,513 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.00 to $23.31. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| March 25, 2019 Filed Mar 28, 2019 00:33 UTC |
Schwab GiselaPres, Prod Dev & Med Aff & CMO
|
Exercise / conversionCommon Stock | 100,000 | $7.18 | $718,000.00 |
DisclosureSEC source: 0000939767-19-000071 · wf-form4_155373321327183.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 416,513 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 66,250 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| March 14, 2019 Filed Mar 16, 2019 00:10 UTC |
Haley Patrick J.Sr. Vice President, Commercial
|
Exercise / conversionOption (right to buy) · Derivative | 2,000 | $0.00 Strike: $1.76 | $0.00 |
DisclosureSEC source: 0000939767-19-000065 · wf-form4_155269501961768.xml · derivative · entry 5 Haley Patrick J. · CIK 0001692954 · Sr. Vice President, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,375 Underlying: Common Stock · 2,000 shares Expires 2021-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 50,000 shares of Exelixis, Inc. common stock, became fully exercisable on November 17, 2018. Read SEC document |
| March 14, 2019 Filed Mar 16, 2019 00:10 UTC |
Haley Patrick J.Sr. Vice President, Commercial
|
SaleCommon Stock | 2,000 | $25.00 | $50,000.00 |
DisclosureSEC source: 0000939767-19-000065 · wf-form4_155269501961768.xml · nonDerivative · entry 2 Haley Patrick J. · CIK 0001692954 · Sr. Vice President, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,780 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 23, 2018. Read SEC document |
| March 14, 2019 Filed Mar 16, 2019 00:10 UTC |
Haley Patrick J.Sr. Vice President, Commercial
|
Exercise / conversionCommon Stock | 2,000 | $1.76 | $3,520.00 |
DisclosureSEC source: 0000939767-19-000065 · wf-form4_155269501961768.xml · nonDerivative · entry 1 Haley Patrick J. · CIK 0001692954 · Sr. Vice President, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,780 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 49,234 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| March 14, 2019 Filed Mar 16, 2019 00:25 UTC |
SCANGOS GEORGE ADirector
|
SaleCommon Stock | 5,000 | $25.00 | $125,000.00 |
DisclosureSEC source: 0000939767-19-000067 · wf-form4_155269591670448.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,318,031 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 24, 2018. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.01. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| March 13, 2019 Filed Mar 16, 2019 00:07 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
Exercise / conversionOption (right to buy) · Derivative | 40,000 | $0.00 Strike: $5.56 | $0.00 |
DisclosureSEC source: 0000939767-19-000063 · wf-form4_155269485960427.xml · derivative · entry 6 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,000 Underlying: Common Stock · 40,000 shares Expires 2019-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option, representing the right to purchase a total of 402,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 21, 2016. Read SEC document |
| March 13, 2019 Filed Mar 16, 2019 00:07 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
SaleCommon Stock | 28,367 | $24.80 | $703,501.60 |
DisclosureSEC source: 0000939767-19-000063 · wf-form4_155269485960427.xml · nonDerivative · entry 3 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2018. F4 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $24.68 to $24.98. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 4 to this Form 4. Read SEC document |
| March 13, 2019 Filed Mar 16, 2019 00:07 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
SaleCommon Stock | 11,633 | $24.24 | $281,983.92 |
DisclosureSEC source: 0000939767-19-000063 · wf-form4_155269485960427.xml · nonDerivative · entry 2 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,367 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2018. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.68 to $24.67. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| March 13, 2019 Filed Mar 16, 2019 00:07 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
Exercise / conversionCommon Stock | 40,000 | $5.56 | $222,400.00 |
DisclosureSEC source: 0000939767-19-000063 · wf-form4_155269485960427.xml · nonDerivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 90,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| March 11, 2019 Filed Mar 14, 2019 00:03 UTC |
Haley Patrick J.Sr. Vice President, Commercial
|
SaleCommon Stock | 959 | $23.13 | $22,181.67 |
DisclosureSEC source: 0000939767-19-000061 · wf-form4_155252179159647.xml · nonDerivative · entry 1 Haley Patrick J. · CIK 0001692954 · Sr. Vice President, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,780 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 23, 2018. F2 · balance_after: Includes 49,234 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| March 01, 2019 Filed Mar 2, 2019 01:17 UTC |
SCANGOS GEORGE ADirector
|
SaleCommon Stock | 40,000 | $22.66 | $906,400.00 |
DisclosureSEC source: 0000939767-19-000054 · wf-form4_155148942126390.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,323,031 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 24, 2018. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.45 to $22.93. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 01:19 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
Exercise / conversionOption (right to buy) · Derivative | 40,000 | $0.00 Strike: $5.56 | $0.00 |
DisclosureSEC source: 0000939767-19-000056 · wf-form4_155148957562576.xml · derivative · entry 5 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,000 Underlying: Common Stock · 40,000 shares Expires 2019-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option, representing the right to purchase a total of 402,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 21, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.